
Chinese specialty biopharmaceutical company founded in 2014 in Shanghai in-licensing and commercialising innovative therapies for China and the Asia-Pacific across four areas - respiratory, including the first-in-class COPD inhibitor ensifentrine, critical care with the Aerofact neonatal surfactant, iron deficiency anaemia with the Niferex range, and pain management - with five marketed products, four programmes in development and about 200 staff.
Xem hồ sơ công ty
Để lại đánh giá